Servier, Prognomix Agree to ID Targets for Diabetes, Metabolic Disease Treatments | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.